Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
About this trial
This trial is enrolling 558 individuals with chronic pain due to central nervous system disorders to test the effect and tolerability of a drug, AP707, on pain. This drug modifies certain neurotransmitters (endocannabinoids) that regulate key bodily functions. If included, participants will receive either AP707 or placebo over the course of 14 weeks. Changes in pain intensity, quality of life, sleep quality, and other measures will be monitored during the study . Final testing will be performed at the end of the 14 weeks.
Included participants
What’s involved
Type
Details
There are no details yet
Potential benefits
Main benefits
Pain
Additional benefits
General health
Mental health and psychosocial factors
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Recruiting
- Trial start date
- 2 Nov 2023
- Organisation
- Apurano Pharmaceuticals GmbH
- Trial recruitment status
- Recruiting
- Trial start date
- 2 Nov 2023
- Organisation
- Apurano Pharmaceuticals GmbH
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more